NCT03000270

Brief Summary

Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2017

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 12, 2016

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 22, 2016

Completed
4 months until next milestone

Study Start

First participant enrolled

April 11, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 19, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2018

Completed
Last Updated

May 6, 2019

Status Verified

November 1, 2018

Enrollment Period

1.2 years

First QC Date

December 12, 2016

Last Update Submit

May 2, 2019

Conditions

Keywords

Infarct SizeImpellaUnloadingLeft VentriclePPCISTEMI

Outcome Measures

Primary Outcomes (2)

  • Infarct size at 30 Days

    Assessment of infarct size as percent of left ventricular (LV) mass, evaluated using CMR, at 30 days post-PPCI

    30 Days

  • MACCE at 30 Days

    A composite of the following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) at 30 days: * Cardiovascular mortality * Re-infarction * Stroke/TIA * Major vascular complication

    30 Days

Secondary Outcomes (6)

  • Infarct Characteristics - LV mass

    3 - 5 and 30 Days

  • Infarct Characteristics - area at risk

    3 - 5 and 30 Days

  • 30 Day Safety Endpoint Rates

    30 Days

  • Infarct Characteristics microvascular obstruction

    3-5 and 30 Days

  • Left Ventricular Function- LV end systolic and diastolic volume index

    3-5 and 30 Days

  • +1 more secondary outcomes

Study Arms (2)

Prolonged unloading prior to PPCI

ACTIVE COMPARATOR

Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention

Device: Impella unloading prior to PPCI

Immediate unloading prior to PPCI

ACTIVE COMPARATOR

Activation of Impella CP immediately prior to primary percutaneous coronary intervention

Device: Impella unloading prior to PPCI

Interventions

Impella unloading prior to PPCI

Immediate unloading prior to PPCIProlonged unloading prior to PPCI

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 21-80 years
  • First myocardial infarction
  • Acute anterior STEMI with ≥ 2 mm in 2 or more contiguous anterior leads or≥ 4 mm total ST-segment deviation sum in the anterior leads
  • Signed Informed Consent

You may not qualify if:

  • Cardiogenic shock defined as: systemic hypotension (systolic BP less than 90 mmHg or the need for inotropes/pressors to maintain a systolic BP Greater than 90mmHg) plus one of the following: any requirement for pressors/inotropes prior to arrival at the cath lab, clinical evidence of end organ hypoperfusion, lactate level greater than 2.5mmol/L
  • Inferior STEMI or suspected right ventricular failure
  • Suspected or known pregnancy
  • Suspected active infection
  • History or known hepatic insufficiency prior to catheterization
  • On dialysis therapy
  • Known contraindication to:
  • Undergoing MRI or use of gadolinium
  • Heparin, pork, pork products or contrast media
  • Receiving a drug-eluting stent
  • Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Banner Good Samaritan Medical Center

Phoenix, Arizona, 85006, United States

Location

Wellstar/Kennestone Hospital

Marietta, Georgia, 30060, United States

Location

Detroit Medical Center

Detroit, Illinois, 48201, United States

Location

Advocate Edward Hospital

Oakbrook Terrace, Illinois, 60089, United States

Location

Tufts Medical Center

Boston, Massachusetts, 02111, United States

Location

ABIOMED, Inc.

Danvers, Massachusetts, 01923, United States

Location

Baystate Medical Center

Springfield, Massachusetts, 01199, United States

Location

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Location

Spectrum

Grand Rapids, Michigan, 49503, United States

Location

Hackensack Medical Center

Hackensack, New Jersey, 07601, United States

Location

University of Buffalo Hospital

Buffalo, New York, 14203, United States

Location

Northwell Health

Manhasset, New York, 11030, United States

Location

Albert Einstein Medical Center

Philadelphia, Pennsylvania, 19141, United States

Location

Greenville Health System

Greenville, South Carolina, 48201, United States

Location

West Virginia University Hospital

Morgantown, West Virginia, 26506, United States

Location

Related Publications (1)

  • Kapur NK, Alkhouli MA, DeMartini TJ, Faraz H, George ZH, Goodwin MJ, Hernandez-Montfort JA, Iyer VS, Josephy N, Kalra S, Kaki A, Karas RH, Kimmelstiel CD, Koenig GC, Lau E, Lotun K, Madder RD, Mannino SF, Meraj PM, Moreland JA, Moses JW, Kim RL, Schreiber TL, Udelson JE, Witzke C, Wohns DHW, O'Neill WW. Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial Infarction. Circulation. 2019 Jan 15;139(3):337-346. doi: 10.1161/CIRCULATIONAHA.118.038269.

Related Links

MeSH Terms

Conditions

ST Elevation Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 12, 2016

First Posted

December 22, 2016

Study Start

April 11, 2017

Primary Completion

June 19, 2018

Study Completion

August 16, 2018

Last Updated

May 6, 2019

Record last verified: 2018-11

Data Sharing

IPD Sharing
Will not share

Locations